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Oxidative stress, a risk factor in the pathophysiology of Alzheimer’s disease, is intimately associated
with aging. We previously reported that the X-XOD free radical generating system acts as a modu-
lator of lipid metabolism and a mild inducer of apoptotic death. Using the same cell model, the pres-
ent study examines the metabolism/processing of the amyloid precursor protein (APP). Prior to
inducing cell death, X-XOD promoted the secretion of a-secretase-cleaved soluble APP (sAPPa)
and increased the level of APP carboxy-terminal fragments produced by a and c secretase (aCTF
and cCTF/AICD). In contrast, it reduced the activity of b-secretase and the level of secreted Ab. The
present results indicate that mild oxidative stress maintained throughout culturing regulates APP
metabolism/processing in SK-N-MC human neuroblastoma cells.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Alzheimer’s disease (AD) is an age-related disorder character-
ized by progressive memory loss and cholinergic neurodegenera-
tion [1]. The disease is associated with a variety of pathological
features in the brain, such as extracellular senile plaques and intra-
cellular neuroﬁbrillary tangles. The main component of these se-
nile plaques is b-amyloid peptide (Ab), which is derived from
amyloid precursor protein (APP), a type I transmembrane protein.
APP is cleaved by three proteases: a-, b-, and c-secretase.
Cleavage by a-secretase occurs within the Ab domain, preventing
the formation of Ab and resulting in the production of a secreted
ectodomain of APP (sAPPa) plus a shorter COOH-terminal frag-
ment of APP (aCTF). The latter is further cleaved by the c-secre-
tase complex, resulting in cCTF/AICD (the APP intracellular
domain) [2]. It is reported that sAPPa is neurotrophic [3,4]. Ab
is generated from APP through proteolytic cleavage by b-secretase
at the b-site, followed by c-secretase cleavage at the position of
downstream amino acid residues 40 or 42; this generates Ab1–40
or Ab1–42, respectively.
Oxidative stress (OS) increases with age [5]. Many studies have
recorded OS in the brains and peripheral tissues of patients with
AD, as well as in animal models of the disease [6]. The xanthine/chemical Societies. Published by E
o).
k.xanthine oxidase (X-XOD) system is a free radical-generating sys-
tem that induces cell death in cerebellar granule neuronal cultures
via reactive oxygen species (ROS) [20]. In earlier work we adapted
this system to generate a human neuronal cell model of mild OS
that allowed the analysis of free radical-induced events preceding
cell death [21]. Using this model, the present study investigates
in vitro the consequence of OS on APP metabolism/processing.
The results show that, in the SK-N-MC human neuroblastoma cell
line, the X-XOD system increases the intracellular level of non-
amyloidogenic CTF (aCTF) and the secretion of sAPPa prior to cell
death. Further, it reduces the secretion of Ab (Ab1–40 and Ab1–42)
leading to the intraneuronal accumulation of APP-derived frag-
ments: CTFs (aCTF, and later bCTF) and sAPPa. The data provided
support a model for the regulation of APP metabolism/processing
as an early response to OS.
2. Materials and methods
2.1. Materials
The cells used in this work were SK-N-MC human neuroblas-
toma cells obtained from the American Type Culture Collection
(HTB-10; ATCC), and SK-N-MC cells overexpressing APP 695 (the
C2 cell line) [8]. Xanthine (X) and catalase were purchased from
Sigma, xanthine oxidase (XOD) from Roche, and trolox from Cal-
biochem. Culture medium components were purchased from Gibco
Laboratories. Other chemicals were purchased from Merck or
Sigma.lsevier B.V. All rights reserved.
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Cells were cultured inminimal essentialmedium (MEM) supple-
mented with 10% foetal bovine serum, 100 mU/ml penicillin G and
100 lg/ml streptomycin in a humidiﬁed atmosphere of 95% air
and 5% CO2. One day before stimulation with X-XOD, exponentially
growing cells at 80–90% conﬂuence were placed in culture dishes
with six multiwells (M-6). On the day of stimulation, the cells were
placed in freshmedium in the presence or absence of an antioxidant
product (trolox or catalase; see below) 1 h before X-XOD treatment.
This was performed as previously described [21].
2.3. Analysis of cell injury
The extent of cell injury after exposure to OS was evaluated
using the 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl tetrazolium
bromide (MTT) assay [7] with minor modiﬁcations [21].
2.4. Preparation of the culture medium for analysis following X-XOD
treatment
After X-XOD treatment, samples of culture medium were col-
lected, centrifuged and concentrated 10-fold by lyophilization in
the presence of a protease inhibitor cocktail (2.5 mM EDTA,
10 lM leupeptin, 1 lM peptastin, 1 mM phenylmethylsulphonyl
ﬂuoride). Samples were then stored at 70 C until their use in
Western blotting analysis or sandwich ELISA.
2.5. APP speciﬁc antibodies
Anti-APP antibody MAB348/22C11 (Chemicon International,
Inc.), or monoclonal antibody 6E10 (Covance), or the anti-C termi-
nal fragment (antibody C1, a kind gift of Paul Mathews, or alterna-
tively rabbit anti-amyloid precursor protein C-terminal fragment
from Sigma) were used for the immunodetection of APP and its
proteolytic fragments. The ability of each antibody to recognize
the different fragments, according to their epitope location in
APP, is summarized below (X indicates recognition). Antibodies
speciﬁc for Ab1–40 or Ab1–42 (Biosource International) were used
where indicated.Antibody holoAPP sAPPa sAPPb aCTF bCTF cCTF/
AICDAb22C11 X X X
6E10 X X X X
Anti-Ct X X X X2.6. Ab detection by sandwich ELISA
Monoclonal antibody 6E10 was used as the capture antibody,
and antibodies speciﬁc for Ab1–40 or Ab1–42 as detection antibodies
(Biosource International). The assays were performed as described
previously [8].
2.7. Western blotting
The concentrations of APP, or alternatively of CTFs, were evalu-
ated by Western blotting. Cells were washed in cold phosphate
buffer saline (PBS) and lysed in Laemmli’s SDS sample buffer before
loading onto 8 or 10–16.5% SDS–polyacrylamide gels. Cell-num-
ber-equivalent samples were subjected to Western blotting. Pro-
tein bands were transferred to nitrocellulose membranes
(BioRad). These membranes were further processed by incubating
with the 22C11, 6E10 or anti-Ct antibodies for 2 h at room temper-
ature. This was followed by incubation with secondary antibody(anti-mouse/horse [Vector Laboratories] horseradish peroxidase
conjugate or anti-rabbit/goat [Nordic] horseradish peroxidase con-
jugate) and visualization of the bands using the enhanced chemilu-
minescence Western-blotting analysis system (Pharmacia
Biotech). As an internal control, a-tubulin levels were examined
(via the reaction with anti-a-tubulin [Sigma]) in the same blots.
2.8. Immunoﬂuorescence confocal microscopy
Cells grown on coverslips and incubated with X-XOD were
ﬁxed with 4% paraformaldehyde in PBS at room temperature for
20 min and permeabilized with PBS containing 0.2% Triton X-
100 and 2% horse serum at 4 C overnight. To examine intraneu-
ronal APP fragments, double labelling with the monoclonal anti-
body 6E10 and the polyclonal antibody directed against the C-
terminus of APP was performed. Cells were incubated at room
temperature for 2 h with primary antibodies and following rinses
were incubated at room temperature for 1 h with Alexa 488 anti-
mouse immunoglobulin G (green) (Invitrogen) and Alexa 555
anti-rabbit immunoglobulin G (red) (Invitrogen). For staining of
the nucleus, coverslips were incubated in PBS containing 5 lg/
ml DAPI (Sigma) at room temperature for 15 min. Cells were
examined using a Zeiss LSM510 META confocal microscope or a
Zeiss Axiovert 200 ﬂuorescence microscope equipped with a
63 oil-immersion objective. Pictures were taken with a digital
camera Spot RT slider (Diagnostic) using the MetaMorph™ imag-
ing system software package. Images were processed using Adobe
Photoshop CS3.
2.9. b-Secretase activity
b-Secretase activity was determined using ﬂuorogenic pep-
tide substrate IV (R&D Systems). The cells were lysed using
100 ll of cell extraction buffer (0.5% sodium deoxycholate, 1%
NP-40 in PBS, pH 7.1), centrifuged at 10 000g for 20 min at
4 C, and the supernatant removed. Protein quantiﬁcations were
made using the Bradford protein assay (BioRad). The superna-
tants were transferred (100 ll/well; 10 lg total protein) to 96-
well microplates with 100 ll of 2 reaction buffer (40 mM
MES, 20% glycerol, 4 mM DTT, pH 5.0) and 1.5 ll of substrate
in each well; the wells were then made up to 200 ll with
Milli-Q water. Plates were incubated in the dark for 18 h at
37 C. Fluorescence was read using a Fluoroskan II Neonat (Flow
Laboratories) (excitation and emission wavelengths 320 and
405 nm, respectively).
2.10. Reactive oxygen species (ROS) assay
The ROS assay was modiﬁed from previously described tech-
niques [22]. Brieﬂy, M-96 plates were seeded at 40 000 cells/well
and after exposure to different treatments were rinsed twice in
HKRB (20 mM HEPES, 103 mM NaCl, 4.77 mM KCl, 0.5 mM CaCl2,
1.2 mM MgCl2, 1.2 mM KH2PO4, 25 mM NaHCO3, 15 mM glucose,
pH 7.3). They were then incubated in a 30 lM solution of 2,7-
dichlorodihydroﬂuorescein diacetate, H2DCFDA (Molecular Probes)
for 3 h, shielded from the light. They were then washed twice with
HKRB and incubated in 200 ll of HKRB at 37 C for 60 min. The
H2DCFDA ﬂuorescence was recorded using an Inﬁnite 200 micro-
plate reader (Tecan Trading AG) at excitation/emission wave-
lengths of 485/535 nm.
2.11. Statistics
Results were expressed as means ± standard errors. Statistical
differences were determined using the Student t test. Signiﬁcance
was set at P < 0.05.
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3.1. X-XOD increased sAPPa secretion in SK-N-MC cells prior to
inducing cell injury
The effects of OS on sAPP secretion were examined by Western
blot analysis using the 6E10 antibody, which recognizes secreted
APP derived from non-amyloidogenic a-cleavage (sAPPa). The re-
sults (Fig. 1A) showed a ﬁvefold increase in sAPPa in the culture
medium of cells treated for 24 h with X-XOD compared to control
cells; at later culture times (48 h), sAPPa levels in the treated cells
were higher but the difference with respect to control cells was not
signiﬁcant. Analysis of the same culture media with the antibody
22C11, which recognizes all the secreted forms of APP (total sAPP),
returned results similar to those above (double those at 24 h of X-
XOD treatment, not shown), suggesting that sAPPa is the major
form of sAPP induced by X-XOD at early treatment times.
To determine whether the promotion of sAPPa release by X-
XOD was the result of an increase in the quantity of cellular APP,
the APP protein was sought in cellular lysates by Western blot
analysis using the 22C11 antibody, which recognizes full-length
APP (holoAPP; hAPP) and the APP fragments containing the N-ter-
minal (sAPP) (see Section 2). The results (Fig. 1B) showed that
treatment with X-XOD for 24 h had no signiﬁcant effect on cellular
APP levels. Similarly, in a previous study using whole genome
expression microarrays, no changes in mRNA after 24 h of X-XOD
treatment were detected [21]. At longer exposure times (48 h),
an increase in 22C11-immunoreactivity became evident, repre-
senting approximately three times the total APP with respect toFig. 1. The X-XOD system increased sAPPa secretion. SK-N-MC cells were subjected to
times (h). (A) sAPPawas analysed by Western blotting with the 6E10 antibody. A represe
expressed as a percentage of the 24 h control for three independent experiments (*P
intracellular sAPP detected by Western blotting with the 22C11 antibody. A representativ
In the lower panel the band corresponds to a-tubulin. The graph shows means ± S.E.M
percentage of the 24 h control for three independent experiments (*P < 0.05 compared
terminal antibody. A representative gel is shown of cultures treated with X-XOD for 24 hcontrol cells (Fig. 1B). The two protein bands recognized by
22C11 corresponded to hAPP (upper band) and sAPP (lower band)
according to their apparent molecular weight and because the
upper band was also recognized by a C-terminal speciﬁc antibody,
whereas the lower band was not (Fig. 1C).
The cell damage induced by X-XOD was assessed. Cell viability
was measured using the MTT assay (Fig. 2) at 24 and 48 h of treat-
ment. While at 48 h the loss of viability was signiﬁcant, at 24 h no
adverse effects were seen. These results agree with previous data
showing minimal apoptotic signals at this treatment time [21].
Together, the above results indicate that, at a time preceding
the transmission of cell death signals, X-XOD promoted sAPPa re-
lease into the culture medium without signiﬁcantly affecting APP
expression. It is therefore concluded that, at early X-XOD treat-
ment times, the promotion of sAPPa secretion might be due to in-
creased activity of the a-secretase processing pathway. The
situation was more complex at prolonged treatment times, when
X-XOD also modulated APP expression.
3.2. The X-XOD system increased CTF levels in the SK-N-MC cells
The carboxy-terminal fragments of APP – aCTF, bCTF and cCTF/
AICD – that remained associated with the cells were monitored by
Western blotting using the C-terminal speciﬁc antibodies.
X-XOD treatment induced a strong increase in the levels of aCTF
and cCTF/AICD (Fig. 3A). As occurred with secreted sAPPa (Fig. 1A),
the intracellular increase in aCTF was highest and most signiﬁcant
at 24 h, conﬁrming the activation of the a-secretase processing
pathway at this time. The 6E10 antibody was used to speciﬁcally10 lM xanthine/50 mU/ml xanthine oxidase (X-XOD) for the indicated incubation
ntative gel is shown. The graph shows the means ± S.E.M. of the densitometry values
< 0.05 compared to 24 h control [Student t test]). (B) Full length APP (hAPP) and
e gel is shown; the bands correspond to the hAPP protein and the intracellular sAPP.
. of densitometry values normalised against a-tubulin. Values are expressed as a
to 24 h control [Student t test]). (C) Intracellular sAPP is not detected with the C-
and analysed by Western blotting with the 22C11 and anti C-terminal antibodies.
Fig. 2. Cell injury induced by the X-XOD system. SK-N-MC cells were subjected to
10 lM xanthine/50 mU/ml xanthine oxidase (X-XOD) for the indicated incubation
times (h) and analysed for injury using the MTT reduction assay. Values are
expressed relative to the optical density of untreated control cells at 570 nm. Each
value represents the average of three replicates ± S.E.M. (*P < 0.05 compared to the
24 h [Student t test], ##P < 0.01 compared to 48 h control).
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followed by an increase at 48 h; this time course could be due toFig. 3. The X-XOD system increased the levels of aCTF and cCTF/AICD. SK-N-MC cell
indicated incubation times (h). (A) APP C-terminal fragments (aCTF, bCTF, and cCTF
representative gel is shown; the band corresponds to the APP C-terminal fragment.
means ± S.E.M. of the densitometry values normalised to a-tubulin. Values are expressed
analysed by Western blotting with the 6E10 antibody. A representative gel is show
means ± S.E.M. of the densitometry values normalised to a-tubulin. Values are expressed
activity in SK-N-MC cells exposed to X-XOD. The graph shows the means ± S.E.M.; values
(*P < 0.05 compared to 24 h control [Student t test]).signiﬁcantly reduced b-secretase activity at 24 h, which recovers
at 48 h (Fig. 3C).
The accumulation of aCTF and cCTF/AICD might be a normal
cellular response to mild OS since, when other human neuroblas-
toma cells (SHSY5Y) were treated for 24 h with X-XOD, aCTF and
cCTF/AICD accumulation was also detected (not shown).
These results suggest that mild OS activates the a-secretase
proteolysis pathway, which is probably a survival response. The
activation of b-secretase and the accumulation of APP fragments
derived from this processing are later events induced in parallel
with death pathways.
3.3. Antioxidants modulate the accumulation of a-secretase-derived
APP fragments induced by X-XOD
The participation of ROS in the regulation of APP metabolism in-
duced by the X-XOD system was assessed using ROS scavengers.
Using the ROS-sensitive probe H2DFCDA, investigations were made
into whether X-XOD actually induces an increase in ROS, and
whether the antioxidants catalase and trolox [23,24] modulate
these ROS concentrations in the present cell model. X-XOD induced
an increase in the levels of ROS that was inhibited by thes were subjected to 10 lM xanthine/50 mU/ml xanthine oxidase (X-XOD) for the
/AICD) were analysed by Western blotting with the anti-C-terminal antibody. A
In the lower panel the bands corresponds to a-tubulin. The graph shows the
as percentages of the 24 h control for three independent experiments. (B) bCTF was
n. In the lower panel the band corresponds to a-tubulin. The graph shows the
as percentages of the 24 h control for three independent experiments (C) b-secretase
are expressed as percentages of the 24 h control for three independent experiments
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Further, catalase and trolox induced a signiﬁcant recovery of the
loss of cellular viability caused by X-XOD, indicating that the effect
of X-XOD on cellular viability was indeed mediated by ROS (not
shown).
Interestingly, the doses of antioxidants partially inhibiting the
increase in ROS levels induced by X-XOD further enhanced the in-
crease in intracellular levels of aCTF (Fig. 4A and B) without affect-
ing APP levels (not shown). This enhancement was particularly
evident when the relative quantities of a and bCTF were measured
(Fig. 4C).
Together, these data suggest that non-amyloidogenic a-cleav-
age of APP is elicited as a cellular response to OS, and that this re-
sponse is activated more strongly when the OS is mild.
3.4. The X-XOD system reduced Ab secretion and led to the
intraneuronal accumulation of the APP-derived fragments CTFs and
sAPPa
Since the quantity of Ab peptide produced by the SK-N-MC
cells was undetectable, SK-N-MC cells that stably overexpress
APP 695 – the C2 cell line [8] – were employed to monitor
changes in Ab. In the X-XOD-treated C2 cells, increases in aCTF
and cCTF/AICD were seen without signiﬁcant changes in APP
expression, as was recorded in the parental SK-N-MC cell line.
Cell viability loss at 24 h and 48 h was also similar to that seen
for the parental cell line (data not shown). This suggests thatFig. 4. Effects of catalase and trolox on the increase of aCTF induced by X-XOD. After 1 h
were subjected to 10 lM xanthine/50 mU/ml xanthine oxidase (X-XOD) for 24 h. APP C-te
terminal antibody. Representative gels are shown for catalase (A) and trolox (B); the ban
graphs show the means ± S.E.M. of the densitometry values normalised to a-tubulin. Valu
and for three independent experiments. (C) Cells were pretreated with trolox and then cu
distinguishing the bands for aCTF and bCTF is shown. The graph shows the relative quaX-XOD-induced APP processing via a-secretase is independent
of the basal APP expression level.
The two main species of amyloid peptide, Ab1–40 and Ab1–42,
were quantiﬁed using sandwich ELISA. Fig. 5A shows that the lev-
els of secreted Ab1–40 or Ab1–42 were signiﬁcantly reduced at 24 h
of X-XOD treatment, followed by a partial recovery of control levels
at 48 h.
Attempts were made to conﬁrm and extend the ﬁndings made
by Western blotting by performing immunoﬂuorescence analyses
aimed at determining the cellular localization of the APP frag-
ments. The C2 line was used since bCTF (and probably Ab) repre-
sent a relatively small proportion of the total APP fragments and
are therefore particularly difﬁcult to monitor in the parental line
(see Fig. 4B). Double immunoﬂuorescence labelling of C2 cells ex-
posed to X-XOD for 24 h was undertaken, using the 6E10 antibody
(green) and the C-terminal speciﬁc antibody (red) to generate con-
focal images (Fig. 5B). The 6E10-immunoreactive protein species is
probably composed of hAPP, sAPPa, bCTF and a small amount of Ab
peptide. The C-terminal-positive staining might correspond to
hAPP and CTFs. However, the absence of staining in the control
cells by the anti-Ct antibody indicates that, at least in these immu-
noﬂuorescence experiments, anti-Ct positive signals are due only
to CTFs.
In the control cells, the 6E10-positive structures were small ves-
icles distributed throughout the cytoplasm. The X-XOD treatment
led to the accumulation of three types of structure according to
their location and staining: (i) 6E10-positive and C-terminalof pretreatment with different concentrations of catalase or trolox, SK-N-MC cells
rminal fragment aCTF and bCTF were analysed by Western blotting with the anti-C-
d corresponds to aCTF. In the lower panel the bands corresponds to a-tubulin. The
es are expressed as percentage of the 24 h X-XOD in the absence of the antioxidant
ltured in the absence or presence of X-XOD for 24 h as described in Section 2. A gel
ntities of a and bCTF.
Fig. 5. The X-XOD system reduced Ab secretion and produced the intraneuronal accumulation of APP derived fragments: CTFs and sAPPa. (A) Ab secretion in C2 cells (SK-N-
MC cells that stably overexpress APP 695) were subjected to 10 lM xanthine/50 mU/ml xanthine oxidase (X-XOD) for the indicated incubation times (h). Quantiﬁcation by
sandwich ELISA speciﬁc for Ab1–40 and Ab1–42 in the culture medium. The graph shows the means ± S.E.M. of the optical density values expressed as percentages of the 24 h
control for three independent experiments (*P < 0.05 compared to 24 h control [Student t test], #P < 0.05 compared to 48 h control). (B) C2 cells subjected to X-XOD for 24 h
examined by double-label confocal microscopy to identify intracellular sAPPa and CTFs. The representative panel shows immunoﬂuorescence images for the 6E10 (green) and
anti C-terminal (red) antibodies. The overlay (yellow) of both antibodies is shown in R1 (region of interest). Phase contrast images are also shown. All images were acquired
using a Zeiss confocal microscope. For each cell culture, six microscopic ﬁelds of three independent cultures were analysed.
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near the plasma membrane; given their immunoreactive proﬁle,
these clusters are probably vesicular structures containing sAPPa,
similar to those described in cell cultures of several lineages
including primary hippocampal neurons exposed to Ab peptide
[19] (which also induces OS); (ii) C-terminal-positive and 6E10-
negative (red-only) structures, mainly located in cytoplasmic ves-
icles (Golgi?) (well known subcellular sites of APP cleavage and
subsequent production of CTFs and sAPP) which would be com-
posed of aCTF, and (iii) structures positive for both the C-terminal
and 6E10 antibodies (yellow); these could be of two types, contain-
ing sAPPa and CTFs together or bCTF exclusively. The Western blot
data suggest that the majority of the yellow signals correspond to
vesicles containing CTFs and sAPPa. The early accumulation of
bCTF with small amounts of Ab has been associated with pre-pla-
que amyloid-associated neuropathology [25].4. Discussion
The cause of neuronal loss in AD seems to be associated with in-
creased OS caused by the peroxidation of lipids [9], as well other
oxidative changes in proteins and DNA [10] – processes that could
be attenuated by antioxidants [11]. Indeed, free radical production
has been implicated in the progression of several neurodegenera-
tive diseases and in the aging process [12].
The present results indicate that OS leads to increased levels of
the APP non-amyloidogenic carboxy terminal fragment (aCTF) at
the time of minimal oxidation-induced neuronal death. After just
24 h of X-XOD treatment, when the viability of the SK-N-MC cells
remained unaffected, increased sAPPawas seen in the culturemed-
ium and no signiﬁcant change in the cellular expression of hAPP
was noticed. sAPPa has trophic effects on cerebral neurons in cul-
ture, stimulates neurite outgrowth, and regulates synaptogenesis
M. Recuero et al. / FEBS Letters 584 (2010) 4611–4618 4617[4]. Previous work has shown that sAPPa exerts neuroprotective ef-
fects, such as the rescue of neurons from the neurotoxic insult in-
duced by Ab, and the increased expression of certain survival
genes [13].
However, at 48 h, the time of cell death, an increase in intracel-
lular sAPPawas seen, although its secretion to the culture medium
was not signiﬁcant. An increase in hAPP levels was also recorded in
agreement with the increase in APP mRNA detected from 36–48 h
(data not shown). This increase in intracellular sAPPa has also been
described in cell cultures of a variety of lineages (including primary
neurons) exogenously exposed to Ab [19]. The Ab peptide has been
shown to induce oxidative stress and the expression of APP [26].
Interestingly, the bCTF levels were slightly reduced at 24 h of
treatment. This, together with the increase in secreted sAPPa, cor-
roborates that the non-amyloidogenic APP processing pathway is
favoured before neuronal death signals become dominant. Catalase
and trolox, which prevented X-XOD-induced cell death, further en-
hanced the increase in aCTF and secreted sAPPa, suggesting a pro-
tective role of a-secretase APP processing in response to OS.
Similar results have recently been described in hippocampal cells
in which the resistance response to OS involves drastic changes
in APP metabolism, in particular aCTF fragment accumulation
and an increase in sAPPa production [27]. At the time of neuronal
death (48 h), the levels of aCTF decreased and those of bCTF in-
creased with respect to their values at 24 h. This must reﬂect a
change in the APP processing/metabolism towards the amyloido-
genic pathway, illustrating that the balance between the a- and
b-secretase pathways is of physiological importance [28,29]. The
recovery of b-secretase activity at 48 h is consistent with the in-
crease in bCTF fragments. bCTF fragments expressed in cells, or
of exogenous origin, cause even more neurotoxicity than Ab [30].
Although the precise functions of CTFs are unknown, they alter
membrane currents and calcium homeostasis [14], stimulate mito-
gen-activated protein kinase pathways, activate the transcription
factor NF-kB, and elevate iNOS [15]. They accumulate in the nu-
cleus and bind to Fe65 [16] and CP2 to alter transcription [15].
The translocation of amyloidogenic CTF to the nucleus has been
implicated in neuronal death in vivo [17].
Recently, the activation of a-secretase and the suppression of
Ab40 secretion by the lipid compound 1,3-capryloyl-2-arachido-
noyl glycerol has been reported [18,31]. In previous work we
showed that the X-XOD system induces the overexpression of
genes related to cholesterol and lipid metabolism [21], and the re-
sults of the present work show this system reduces the secretion of
Ab1–40 and Ab1–42 suggesting a link between OS, lipid metabolism
and APP metabolism. This reduced secretion may be explained by
the reduction (although not complete stoppage) of b-secretase
activity. This would leave a-secretase to cleave the APP molecules
not processed by b-secretase, reﬂected as an increase in sAPPa.
APP proteolytic processing and trafﬁcking are closely related;
indeed, processing can occur in different cell organelles during
intracellular transport [32,33]. Immunoﬂuorescence analysis
involving confocal microscopy showed that, before neuronal death
(i.e., X-XOD treatment for 24 h), amino-(sAPPa) and carboxy-ter-
minal (aCTF rather than bCTF) APP fragments are accumulated.
These appeared in vesicular structures concentrated in the cyto-
plasm, as seen in the production of sAPPa and CTFs [19].
It seems increasingly apparent that OS is a primary progenitor of
AD and not merely an epiphenomenon [34]. The present results
outline a dynamic cell model in which APP proteolytic processing,
and perhaps the catabolism and trafﬁcking of derived fragments,
are modulated by the X-XOD system. These ﬁndings provide strong
evidence for a substantial role for APP and its cleaved products in
selective OS-induced neuronal loss. Monitoring the changes in the
a/b-secretase activity ratio might be a practical way of following
end-stage alterations in the APP processing pathway in responseto different antioxidant treatments. More studies on the novel
mechanisms by which a-secretase activity is regulated by OSmight
lead to a new therapeutic approach in the treatment of AD.Acknowledgements
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